Skip to Content

Remimazolam Approval Status

FDA Approved: No
Generic name: remimazolam
Company: Cosmo Pharmaceuticals NV
Treatment for: Anesthesia

Remimazolam is an ultra-short-acting intravenous benzodiazepine sedative/anesthetic in development for use during gastrointestinal procedures.

Development Status and FDA Approval Process for remimazolam

DateArticle
Apr  9, 2019Cosmo Pharmaceuticals Announces Submission of Remimazolam NDA to FDA
Jun  8, 2015PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Bronchoscopy
Mar 31, 2015Paion Announces Initiation of U.S. Phase III Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide